| |
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about the latest innovations in packaging and aseptic filling solutions that meet the complex demands of emerging therapies. Discover how to ensure product integrity, safety and efficiency. Register now. 
|
|
Today’s Big NewsJan 16, 2025 |
|
Connecting the Innovation Districts in Cincinnati, Columbus and Cleveland, the Ohio Discovery Corridor drives opportunity, innovation, and collaboration unlike anywhere else in the Midwest. Explore the corridor. 
|
|
| By Gabrielle Masson Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. |
|
|
|
By Ben Adams,Gabrielle Masson,Darren Incorvaia,James Waldron Welcome to day 3 of the J.P. Morgan Healthcare Conference in San Francisco. |
By Fraiser Kansteiner Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in blockbuster-level sales down the line. |
By James Waldron Servier is extending its pact with Google Cloud as the French biopharma points to 60 examples of how generative artificial intelligence (gen AI) could improve its drug development processes. |
|
Do you have the instrumentation & experts you need and simply require access to an expansive collection of biospecimens? Or are you in need of an experienced CRO? Either way, BioIVT has you covered! View Options >> 
|
|
By Nick Paul Taylor Avacta is stepping up development of its peptide-drug conjugate, kicking off expansion cohorts in multiple tumor types after seeing one partial response in 10 salivary gland cancer patients. |
By Darren Incorvaia Serina Therapeutics is shedding a subsidiary to start the new year off debt-free. The Alabama-based biotech has sold UniverXome Bioengineering to clear away $11.2 million in debt. |
By Eric Sagonowsky The FDA has issued a complete response letter for Atara's biologics license application "solely related to inspection findings" at a third-party manufacturer, the biotech said. |
By Nick Paul Taylor Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. Now, the biotech has distanced itself from its premerger form by rebranding as Rein Therapeutics. |
By Kevin Dunleavy After a run of court victories in a patent dispute with the U.S. government, Gilead has agreed to settle to resolve the feds’ last-ditch appeal. Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and Descovy for pre-exposure prophylaxis. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into 2024's batch of new FDA drug approvals, highlighting some potential blockbusters and shifts from previous years' lists. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
